CN115887562B - 一种治疗阿尔兹海默症的中药复方提取物及其制备方法 - Google Patents
一种治疗阿尔兹海默症的中药复方提取物及其制备方法 Download PDFInfo
- Publication number
- CN115887562B CN115887562B CN202211604141.5A CN202211604141A CN115887562B CN 115887562 B CN115887562 B CN 115887562B CN 202211604141 A CN202211604141 A CN 202211604141A CN 115887562 B CN115887562 B CN 115887562B
- Authority
- CN
- China
- Prior art keywords
- ethanol
- extract
- water
- rhizoma acori
- acori graminei
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 116
- 239000000284 extract Substances 0.000 title claims abstract description 87
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 52
- 150000001875 compounds Chemical class 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 150
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 28
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 28
- 235000008434 ginseng Nutrition 0.000 claims abstract description 28
- 239000000341 volatile oil Substances 0.000 claims abstract description 28
- 238000001035 drying Methods 0.000 claims abstract description 27
- 238000000605 extraction Methods 0.000 claims abstract description 26
- 238000003809 water extraction Methods 0.000 claims abstract description 23
- 241001080798 Polygala tenuifolia Species 0.000 claims abstract description 19
- 238000001556 precipitation Methods 0.000 claims abstract description 19
- 238000005303 weighing Methods 0.000 claims abstract description 19
- 244000197580 Poria cocos Species 0.000 claims abstract description 15
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 15
- 241000005787 Cistanche Species 0.000 claims abstract description 14
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 14
- 235000005412 red sage Nutrition 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 80
- 238000002156 mixing Methods 0.000 claims description 38
- 239000012141 concentrate Substances 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 30
- 241000208340 Araliaceae Species 0.000 claims description 27
- 230000005484 gravity Effects 0.000 claims description 26
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 17
- 229940055577 oleyl alcohol Drugs 0.000 claims description 17
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims description 17
- 239000008187 granular material Substances 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 16
- 238000010992 reflux Methods 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 14
- 238000007873 sieving Methods 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 13
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 12
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 11
- 239000000469 ethanolic extract Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 238000000498 ball milling Methods 0.000 claims description 8
- 239000007779 soft material Substances 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 7
- 235000019425 dextrin Nutrition 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 7
- 238000005507 spraying Methods 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 238000012869 ethanol precipitation Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 abstract description 18
- 239000000463 material Substances 0.000 abstract description 9
- 238000000338 in vitro Methods 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 5
- 230000004071 biological effect Effects 0.000 abstract description 2
- 238000005457 optimization Methods 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 60
- 108010022752 Acetylcholinesterase Proteins 0.000 description 60
- 229940079593 drug Drugs 0.000 description 39
- 229940022698 acetylcholinesterase Drugs 0.000 description 37
- 238000002474 experimental method Methods 0.000 description 37
- 241000699670 Mus sp. Species 0.000 description 35
- 230000000694 effects Effects 0.000 description 32
- 239000000243 solution Substances 0.000 description 29
- 238000012360 testing method Methods 0.000 description 29
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- 230000005764 inhibitory process Effects 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 18
- 238000002835 absorbance Methods 0.000 description 17
- NTBLZMAMTZXLBP-UHFFFAOYSA-M 2-acetylsulfanylethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=O)SCC[N+](C)(C)C NTBLZMAMTZXLBP-UHFFFAOYSA-M 0.000 description 16
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 14
- 230000015654 memory Effects 0.000 description 14
- ZRJBHWIHUMBLCN-SEQYCRGISA-N huperzine a Chemical compound N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 12
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 11
- 230000009189 diving Effects 0.000 description 11
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- ZPUCINDJVBIVPJ-LJISPDSOSA-N ***e Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 9
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 8
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 238000012549 training Methods 0.000 description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 6
- 230000006978 adaptation Effects 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000000556 factor analysis Methods 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- GANZODCWZFAEGN-UHFFFAOYSA-N 5-mercapto-2-nitro-benzoic acid Chemical compound OC(=O)C1=CC(S)=CC=C1[N+]([O-])=O GANZODCWZFAEGN-UHFFFAOYSA-N 0.000 description 4
- 241000405414 Rehmannia Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001713 cholinergic effect Effects 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- FSBUXLDOLNLABB-ISAKITKMSA-N echinacoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FSBUXLDOLNLABB-ISAKITKMSA-N 0.000 description 4
- NJYVDFDTLLZVMG-UHFFFAOYSA-N echinacoside Natural products CC1OC(OC2C(O)C(OCCc3ccc(O)c(O)c3)OC(COC4OC(CO)C(O)C(O)C4O)C2OC(=O)C=Cc5cc(O)cc(O)c5)C(O)C(O)C1O NJYVDFDTLLZVMG-UHFFFAOYSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 3
- 238000012347 Morris Water Maze Methods 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 239000000544 cholinesterase inhibitor Substances 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000010977 jade Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 3
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 3
- 230000006403 short-term memory Effects 0.000 description 3
- 230000006886 spatial memory Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 2
- 244000001632 Acorus gramineus Species 0.000 description 2
- 235000013073 Acorus gramineus Nutrition 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 2
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 241000208966 Polygala Species 0.000 description 2
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 2
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 2
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 210000004129 prosencephalon Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 2
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 244000205574 Acorus calamus Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 102000017927 CHRM1 Human genes 0.000 description 1
- 235000011996 Calamus deerratus Nutrition 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 1
- 101150073075 Chrm1 gene Proteins 0.000 description 1
- 241000336291 Cistanche deserticola Species 0.000 description 1
- 241000336315 Cistanche salsa Species 0.000 description 1
- 241000336316 Cistanche tubulosa Species 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 240000006711 Pistacia vera Species 0.000 description 1
- 235000003447 Pistacia vera Nutrition 0.000 description 1
- 229930182432 Polygalasaponin Natural products 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229930185474 acteoside Natural products 0.000 description 1
- FBSKJMQYURKNSU-ZLSOWSIRSA-N acteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FBSKJMQYURKNSU-ZLSOWSIRSA-N 0.000 description 1
- FBSKJMQYURKNSU-UKQWSTALSA-N acteoside I Natural products C[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O FBSKJMQYURKNSU-UKQWSTALSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003194 amino acid receptor blocking agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003937 effect on alzheimer disease Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- -1 low dose group Substances 0.000 description 1
- BCZFSDNVXODRAJ-JTTNIQEDSA-N lycopodine Chemical compound C1CCN2CCC[C@@H]3[C@H]4C[C@@H](C)C[C@]32[C@H]1C(=O)C4 BCZFSDNVXODRAJ-JTTNIQEDSA-N 0.000 description 1
- BCZFSDNVXODRAJ-ZHMBSYLPSA-N lycopodine Natural products C1CCN2CCC[C@@H]3[C@H]4C[C@H](C)C[C@]32[C@H]1C(=O)C4 BCZFSDNVXODRAJ-ZHMBSYLPSA-N 0.000 description 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 235000020233 pistachio Nutrition 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- GWHQHAUAXRMMOT-MBANBULQSA-N rivastigmine tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 GWHQHAUAXRMMOT-MBANBULQSA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000010017 yuan zhi Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 平行样1 | 平行样2 | 平行样3 | 均值 |
石杉碱甲组 | 34.70% | 33.50% | 32.94% | 33.7%±0.9% |
本发明药物组 | 32.50% | 33.10% | 33.46% | 33.0%±0.5% |
水提物 | 26.02% | 25.47% | 25.69% | 25.7%±0.3% |
醇提物 | 22.13% | 23.10% | 22.54% | 22.6%±0.5% |
组别 | 平行样1 | 平行样2 | 平行样3 | 均值 |
石杉碱甲组 | 38.15% | 39.24% | 38.53% | 38.6%±0.6% |
本发明药物组 | 39.11% | 39.34% | 38.47% | 39.0%±0.5% |
样品1组 | 21.02% | 20.49% | 21.98% | 21.2%±0.8% |
样品2组 | 29.15% | 29.72% | 30.60% | 29.8%±0.7% |
组别 | 平行样1 | 平行样2 | 平行样3 | 均值 |
石杉碱甲组 | 39.41% | 39.78% | 38.83% | 39.3%±0.5% |
本发明药物组 | 39.56% | 39.84% | 39.17% | 39.5%±0.3% |
样品1组 | 19.02% | 19.96% | 20.11% | 19.7%±0.6% |
样品2组 | 23.64% | 23.10% | 22.85% | 23.2%±0.4% |
样品3组 | 32.26% | 30.89% | 31.74% | 31.6%±0.7% |
组别 | 剂量 | 动物数/只 | 识别指数 |
对照组 | - | 15 | 0.5814±0.06147 |
模型组 | - | 14 | 0.422±0.02834* |
阳性药组 | 26μg/kg | 15 | 0.5443±0.03220# |
开心散组 | 2.5g/kg | 15 | 0.5012±0.03547# |
琼玉膏组 | 2.5g/kg | 15 | 0.4831±0.03112# |
低剂量组 | 1.25g/kg | 15 | 0.5081±0.04122# |
中剂量组 | 2.5g/kg | 15 | 0.5378±0.04617# |
高剂量组 | 5.0g/kg | 15 | 0.5411±0.03555# |
组别 | 剂量 | 动物数/只 | 潜伏期(秒) |
对照组 | - | 15 | 117.45±30.35 |
模型组 | - | 14 | 43.43±10.32* |
阳性药组 | 26μg/kg | 15 | 114.96±28.74# |
开心散组 | 2.5g/kg | 15 | 84.41±24.43 |
琼玉膏组 | 2.5g/kg | 15 | 72.63±25.73 |
低剂量组 | 1.25g/kg | 15 | 106.53±22.911# |
中剂量组 | 2.5g/kg | 15 | 103.37±27.12# |
高剂量组 | 5.0g/kg | 15 | 123.53±10.50# |
组别 | 剂量 | 动物数/只 | 错误次数 |
对照组 | - | 15 | 1.1783±0.1975 |
模型组 | - | 14 | 2.8467±0.3057** |
阳性药组 | 26μg/kg | 15 | 1.7417±0.2836# |
开心散组 | 2.5g/kg | 15 | 2.3132±0.2143 |
琼玉膏组 | 2.5g/kg | 15 | 2.5147±0.2981 |
低剂量组 | 1.25g/kg | 15 | 2.3350±0.4528 |
中剂量组 | 2.5g/kg | 15 | 1.8407±0.3571# |
高剂量组 | 5.0g/kg | 15 | 1.7190±0.5535# |
组别 | 剂量 | 动物数/只 | 逃避潜伏期(秒) |
对照组 | - | 15 | 22.06±3.87 |
模型组 | - | 14 | 43.41±4.16* |
阳性药组 | 26μg/kg | 15 | 25.10±3.89# |
开心散组 | 2.5g/kg | 15 | 36.12±3.24 |
琼玉膏组 | 2.5g/kg | 15 | 39.57±2.83 |
低剂量组 | 1.25g/kg | 15 | 34.48±3.58# |
中剂量组 | 2.5g/kg | 15 | 26.96±4.15# |
高剂量组 | 5.0g/kg | 15 | 25.10±4.23# |
组别 | 剂量 | 动物数/只 | 目标象限路程(mm) |
对照组 | - | 15 | 2934±172.1 |
模型组 | - | 14 | 2641±208.0 |
阳性药组 | 26μg/kg | 15 | 2956±191.4 |
开心散组 | 2.5g/kg | 15 | 2727±202.1 |
琼玉膏组 | 2.5g/kg | 15 | 2136±198.4 |
低剂量组 | 1.25g/kg | 15 | 2758±156.7 |
中剂量组 | 2.5g/kg | 15 | 2503±173.2 |
高剂量组 | 5.0g/kg | 15 | 2904±137.9 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211604141.5A CN115887562B (zh) | 2022-12-13 | 2022-12-13 | 一种治疗阿尔兹海默症的中药复方提取物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211604141.5A CN115887562B (zh) | 2022-12-13 | 2022-12-13 | 一种治疗阿尔兹海默症的中药复方提取物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115887562A CN115887562A (zh) | 2023-04-04 |
CN115887562B true CN115887562B (zh) | 2024-06-04 |
Family
ID=86496139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211604141.5A Active CN115887562B (zh) | 2022-12-13 | 2022-12-13 | 一种治疗阿尔兹海默症的中药复方提取物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115887562B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1171970A (zh) * | 1997-06-26 | 1998-02-04 | 周淑琴 | 具有抗衰老功能的保健酒 |
CN102895432A (zh) * | 2011-07-26 | 2013-01-30 | 王登之 | 开心散新剂型处方工艺及其制备方法 |
CN106266344A (zh) * | 2016-08-31 | 2017-01-04 | 四川光大制药有限公司 | 一种益脑颗粒剂及其制作工艺 |
CN109432267A (zh) * | 2018-12-18 | 2019-03-08 | 吉林修正药业新药开发有限公司 | 一种治疗阿尔茨海默病的中药组合物及其制备方法和应用 |
-
2022
- 2022-12-13 CN CN202211604141.5A patent/CN115887562B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1171970A (zh) * | 1997-06-26 | 1998-02-04 | 周淑琴 | 具有抗衰老功能的保健酒 |
CN102895432A (zh) * | 2011-07-26 | 2013-01-30 | 王登之 | 开心散新剂型处方工艺及其制备方法 |
CN106266344A (zh) * | 2016-08-31 | 2017-01-04 | 四川光大制药有限公司 | 一种益脑颗粒剂及其制作工艺 |
CN109432267A (zh) * | 2018-12-18 | 2019-03-08 | 吉林修正药业新药开发有限公司 | 一种治疗阿尔茨海默病的中药组合物及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
补脑I号对阿尔茨海默病模型大鼠早期淀粉样蛋白和突触结构与功能的影响;赵芝兰;况时祥;薛红;翁柠;;时珍国医国药;-(06);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN115887562A (zh) | 2023-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103784635B (zh) | 一种改善记忆力的益智胶囊及制备方法 | |
CN105920476B (zh) | 防治阿尔茨海默病中药组合物及其制备方法 | |
US20220226413A1 (en) | Traditional chinese medicine composition with improving cognition effect, preparation method thereof and traditional chinese medicine preparation | |
CN109925402B (zh) | 一种中药组合物及其制备方法与应用 | |
CN111588792B (zh) | 一种治疗中风后吞咽困难的中成药 | |
CN102233009A (zh) | 一种促进神经再生的中药组合物及其制备方法和应用 | |
CN115887562B (zh) | 一种治疗阿尔兹海默症的中药复方提取物及其制备方法 | |
CN103768171B (zh) | 抗抑郁、杀菌消炎的中药组合物及其制备方法 | |
CN113813310B (zh) | 一种防治脑部疾病的中药组合物及其制备方法和应用 | |
CN106727898B (zh) | 一种防治阿尔茨海默病的药物组合物及其制备方法 | |
CN105920186B (zh) | 一种用于治疗痔疮的中药组合物及其制备方法 | |
CN108295168B (zh) | 一种治疗卒中后抑郁的中药组合物 | |
CN112641912A (zh) | 一种快速治疗儿童多动症的药物 | |
CN104622993A (zh) | 一种对酒精性肝损伤具有保护作用的咀嚼片及其制备方法 | |
CN111053819A (zh) | 中药组合物提取物及在制备蛋白表达调节剂中的应用 | |
CN110694025A (zh) | 八珍益智复方和制备方法及应用 | |
CN112826901A (zh) | 一种快速缓解老年性痴呆症状的药物 | |
CN115737747B (zh) | 一种用于改善记忆力、防治老年痴呆的中药组合物及其应用 | |
CN110478450B (zh) | 一种治疗阿尔茨海默病的药物组合物及其应用 | |
CN115887573B (zh) | 一种减缓衰老改善脑功能退化的中药组合物和制备方法 | |
CN116870063B (zh) | 一种具有活血安神功能的中药组合物及制备方法 | |
CN108379367A (zh) | 毒品戒断的纯中药药物及其制备方法 | |
CN116115703A (zh) | 一种中药组合物及其制备方法 | |
CN108272917A (zh) | 一种治疗记忆力减退的维吾尔药组合物及其制备方法 | |
JP6708916B1 (ja) | 補気調節用チワン族医薬品組成物及びその調製方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Country or region after: China Address after: Building 2, 5th Floor, No. 333 Songling Road, Laoshan District, Qingdao City, Shandong Province, 266000 Applicant after: Qingdao Chenlan Pharmaceutical Co.,Ltd. Address before: Floor 5, Building 2, No. 333, Songling Road, Laoshan District, Qingdao, Shandong 266100 Applicant before: Qingdao Yisheng Kanghe Biotechnology Co.,Ltd. Country or region before: China |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zou Shengcan Inventor after: Wang Yilei Inventor after: Zong Jiancheng Inventor after: Wang Xue Inventor after: Yin Dongli Inventor after: Liu Tingting Inventor after: Wang Nan Inventor before: Zou Shengcan Inventor before: Zong Jiancheng Inventor before: Wang Yilei Inventor before: Wang Xue Inventor before: Yin Dongli Inventor before: Liu Tingting Inventor before: Wang Nan |
|
GR01 | Patent grant | ||
GR01 | Patent grant |